Secondary endpoints in Serenity Pharmaceuticals LLC's pivotal trials of Noctiva helped to demonstrate the clinical meaningfulness of the desmopressin nasal spray for nocturia, FDA said in its denial of a potential Noctiva competitor's citizen petition.
FDA approved Noctiva, a nasal spray formulation of the vasopressin analog desmopressin, on March 3 for treatment of nocturia due...







